COVERAGE HUB
$COGT
3 articles in last 30 days
LAST 30 DAYS
3 articles
AVG GRADE
LOW
score: -0.33
SENTIMENT
BULLISH
TOTAL VIEWS
0
3-DAY GRADE TIMELINE
2026-06-12
TODAY
RECENT COVERAGE · 3 ARTICLES
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT)
COGT represents a pre-commercial biotech transitioning toward commercial-stage execution through a focused KIT-mutant franchise...
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow (NASDAQ:COGT) 2026-06-13
COGT presented clinical or corporate data at the European Hematology Association 2026 Congress, a standard industry conference attended...
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences (COGT) unveiled preclinical efficacy data for its JAK2 V617F inhibitor candidate at a major European hematology...